These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26343499)

  • 1. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study.
    Giuliano AR; Isaacs-Soriano K; Torres BN; Abrahamsen M; Ingles DJ; Sirak BA; Quiterio M; Lazcano-Ponce E
    Vaccine; 2015 Oct; 33(42):5640-5646. PubMed ID: 26343499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N; Ansah NA; Marino D; Saah A; Garner EI
    Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old.
    Hillman RJ; Giuliano AR; Palefsky JM; Goldstone S; Moreira ED; Vardas E; Aranda C; Jessen H; Ferris DG; Coutlee F; Marshall JB; Vuocolo S; Haupt RM; Guris D; Garner EI
    Clin Vaccine Immunol; 2012 Feb; 19(2):261-7. PubMed ID: 22155768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial.
    Pinto LA; Kemp TJ; Torres BN; Isaacs-Soriano K; Ingles D; Abrahamsen M; Pan Y; Lazcano-Ponce E; Salmeron J; Giuliano AR
    J Infect Dis; 2016 Oct; 214(8):1276-83. PubMed ID: 27511896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.
    Nygård M; Saah A; Munk C; Tryggvadottir L; Enerly E; Hortlund M; Sigurdardottir LG; Vuocolo S; Kjaer SK; Dillner J
    Clin Vaccine Immunol; 2015 Aug; 22(8):943-8. PubMed ID: 26084514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
    Van Damme P; Meijer CJLM; Kieninger D; Schuyleman A; Thomas S; Luxembourg A; Baudin M
    Vaccine; 2016 Jul; 34(35):4205-4212. PubMed ID: 27354258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
    Mikamo H; Yamagishi Y; Murata S; Yokokawa R; Han SR; Wakana A; Sawata M; Tanaka Y
    Vaccine; 2019 Mar; 37(12):1651-1658. PubMed ID: 30797638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gardasil Vaccination for Recurrent Laryngeal Papillomatosis in Adult Men: First Report: Changes in HPV Antibody Titer.
    Makiyama K; Hirai R; Matsuzaki H
    J Voice; 2017 Jan; 31(1):104-106. PubMed ID: 27068425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
    Gilca V; Sauvageau C; Boulianne N; De Serres G; Couillard M; Krajden M; Ouakki M; Murphy D; Trevisan A; Dionne M
    Hum Vaccin Immunother; 2014; 10(8):2438-45. PubMed ID: 25424952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
    Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
    PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD.
    Praditpornsilpa K; Kingwatanakul P; Deekajorndej T; Rianthavorn P; Susantitaphong P; Katavetin P; Tiranathanakul K; Srisawat N; Tungsanga K; Eiam-Ong S; Townamchai N
    Nephrol Dial Transplant; 2017 Jan; 32(1):132-136. PubMed ID: 26932687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
    MacIntyre CR; Shaw P; Mackie FE; Boros C; Marshall H; Barnes M; Seale H; Kennedy SE; Moa A; Hayen A; Chughtai AA; O'Loughlin EV; Stormon M
    Vaccine; 2016 Aug; 34(36):4343-50. PubMed ID: 27406936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
    Brown DR; Garland SM; Ferris DG; Joura E; Steben M; James M; Radley D; Vuocolo S; Garner EI; Haupt RM; Bryan JT
    Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
    Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men.
    Pinto LA; Wilkin TJ; Kemp TJ; Abrahamsen M; Isaacs-Soriano K; Pan Y; Webster-Cyriaque J; Palefsky JM; Giuliano AR
    Vaccine; 2019 Apr; 37(18):2502-2510. PubMed ID: 30940485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus.
    Dhar JP; Essenmacher L; Dhar R; Magee A; Ager J; Sokol RJ
    Vaccine; 2017 May; 35(20):2642-2646. PubMed ID: 28404357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
    Gilca V; Sauvageau C; Boulianne N; De Serres G; Crajden M; Ouakki M; Trevisan A; Dionne M
    Hum Vaccin Immunother; 2015; 11(3):732-8. PubMed ID: 25714044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
    Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.